European Commission grants orphan drug designation to sparsentan for the treatment of IgA nephropathy

Sparsentan is an investigational dual-acting antagonist of both the endothelin type A and angiotensin II type 1 receptors. It is currently being evaluated in Phase III studies for the treatment of IgA nephropathy (PROTECT) and focal segmental glomerulosclerosis (DUPLEX).

Biospace Inc.